Abstract
Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Current Molecular Medicine
Title: Programmed Cell Death Mechanisms in Neurological Disease
Volume: 8 Issue: 3
Author(s): Dale E. Bredesen
Affiliation:
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Abstract: Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Export Options
About this article
Cite this article as:
Bredesen E. Dale, Programmed Cell Death Mechanisms in Neurological Disease, Current Molecular Medicine 2008; 8 (3) . https://dx.doi.org/10.2174/156652408784221315
DOI https://dx.doi.org/10.2174/156652408784221315 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Emerging Biomarkers for Drug Development in Amyotrophic Lateral Sclerosis)
Current Medicinal Chemistry The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets MicroRNAs and Physical Activity
MicroRNA Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Podocyte Mitosis – A Catastrophe
Current Molecular Medicine Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Melatonin Synthetic Analogs as Nitric Oxide Synthase Inhibitors
Mini-Reviews in Medicinal Chemistry Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry Molecular Insights into Mechanisms of the Cell Death Program:Role in the Progression of Neurodegenerative Disorders
Current Alzheimer Research The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research Editorial: Structural Aspects of Protein Aggregation
Protein & Peptide Letters Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry